KINRIX
STN: BL 125260
Proper Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
Tradename: KINRIX
Manufacturer: GlaxoSmithKline Biologicals
Indication:
- KINRIX is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children aged 4 through 6 years (prior to the seventh birthday) whose previous DTaP vaccine doses have been with INFANRIX and/or PEDIARIX for the first 3 doses and INFANRIX for the fourth dose.
Product Information
Supporting Documents
- October 27, 2023 Approval Letter - KINRIX
- July 20, 2023 Approval Letter - KINRIX
- November 23, 2022 Approval Letter - KINRIX
- November 6, 2019 Approval Letter - KINRIX
- Approval History, Letters, Reviews, and Related Documents - KINRIX
- Supporting Documents older than three years - KINRIX